Table 3.
Efficacy at end of therapy
| Primary (%) |
Refractory/toxicity failurea (%) |
Total (%) (N = 225) | |||
|---|---|---|---|---|---|
| Micafungin in combination (n = 17) | Micafungin alone (n = 12) | Micafungin in combination (n = 174) | Micafungin alone (n = 22) | ||
| Complete response | 2 (11.8) | 0 | 13 (7.5) | 3 (13.6) | 18 (8.0) |
| Partial response | 3 (17.6) | 6 (50.0) | 47 (27.0) | 6 (27.3) | 62 (27.6) |
| Favorable response | 5 (29.4) | 6 (50.0) | 60 (34.5) | 9 (40.9) | 80 (35.6) |
| Stabilization | 3 (17.6) | 2 (16.7) | 17 (9.8) | 3 (13.6) | 25 (11.1) |
| Progression | 9 (52.9) | 4 (33.3) | 97 (55.7) | 10 (45.5) | 120 (53.3) |
| Not successful | 12 (70.6) | 6 (50) | 114 (65.5) | 13(59.1) | 145 (64.4) |
a
Four patients who had failed previous therapy due to toxicities are included in the micafungin-alone group.